Search Results

Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, announced positive efficacy activity against Helicobacter pylori bacteria in rats treated with new antibiotic RECCE® 435, including a favorable toxicity profile in a related study.

Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline of GEMMs candidates for inflammatory bowel disease.

Highlights : Murdoch Children’s Research Institute to evaluate the in-vivo antimicrobial activity of RECCE ® 435 oral formulation against Helicobacter pylori (H. pylori) in preclinical studies program Studies led by H. pylori infectious disease expert Professor Philip Sutton Multiple world-first data opportunities over 12 months study program – anticipated human clinical trial beyond SYDNEY, Australia, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Recce Pharma

LumiraDx Limited will be presenting at the Raymond James Institutional Investors Conference on Tuesday, March 7th, 2023 at 4:35pm ET. Webcast link below.